文献速递前列腺癌

在前列腺磁共振靶向穿刺时代,既往穿刺阴性患者是否仍需重复系统穿刺

Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
PubMed 文献 · Eur Urol Oncol · 2019-06-22

该研究为多中心随机对照试验的前瞻性分析,纳入665例既往系统穿刺阴性且持续怀疑前列腺癌的男性,所有患者接受3T多参数磁共振(mpMRI)并按PI-RADS v2评估。在152例同时接受靶向穿刺和系统穿刺的患者中,靶向穿刺检出前列腺癌47% vs 系统穿刺32%(p<0.001,95%CI 6.0-22%),检出临床显著前列腺癌32% vs 16%(p<0.001,95%CI 11-25%);仅1.3%(2/152)的临床显著前列腺癌被靶向穿刺漏诊。作者结论认为重复系统穿刺的附加价值有限。

要点

  • 靶向穿刺检出临床显著前列腺癌32% vs 系统穿刺16%(p<0.001,95%CI 11-25%)。
  • 靶向穿刺漏诊临床显著前列腺癌仅1.3%(2/152)。
  • 联合系统穿刺与单用靶向穿刺相比,临床显著前列腺癌检出率差异仅1.0%。

核心结论

  • 在既往系统穿刺阴性但持续怀疑前列腺癌的患者中,靶向穿刺检出的临床显著前列腺癌显著多于系统穿刺。
  • 重复系统穿刺的附加价值有限,若省略系统穿刺,仅1.3%的临床显著前列腺癌会被漏诊。

研究设计与样本

  • 2014年至2017年开展的多中心随机对照试验中的前瞻性研究,纳入665例既往系统穿刺阴性且持续怀疑前列腺癌的男性。
  • 所有患者接受3T多参数磁共振(mpMRI)并按PI-RADS v2评估;PI-RADS≥3的患者按1:1:1随机分配至三种靶向穿刺技术:MRI-TRUS融合靶向穿刺(FUS-TB)、认知融合靶向穿刺(COG-TB)或MRI室内靶向穿刺。
  • FUS-TB和COG-TB联合重复系统穿刺;共152例患者同时接受靶向穿刺和系统穿刺并纳入分析。

主要发现

  • 在152例同时接受靶向穿刺和系统穿刺的患者中,靶向穿刺检出前列腺癌47%,系统穿刺检出32%(p<0.001,95%CI 6.0-22%)。
  • 靶向穿刺检出临床显著前列腺癌32%,系统穿刺检出16%(p<0.001,95%CI 11-25%)。
  • 靶向穿刺漏诊临床显著前列腺癌1.3%(2/152)。
  • 与单用靶向穿刺相比,联合系统穿刺与靶向穿刺使前列腺癌检出率差异为6.0%,临床不显著前列腺癌检出率差异为5.0%,临床显著前列腺癌检出率差异为1.0%。

关键数值与推荐

  • 临床显著前列腺癌定义为Gleason评分≥3+4。
  • 靶向穿刺与系统穿刺检出率差异采用McNemar检验比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of targeted prostate biopsies (TBs) in patients with cancer suspicious lesions on multiparametric magnetic resonance imaging (mpMRI) following negative systematic biopsies (SBs) is undebated. However, whether they should be combined with repeated SBs remains unclear. OBJECTIVE: To evaluate the value of repeated SBs in addition to TBs in patients with a prior negative SB and a persistent suspicion of prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: A prospective study as part of a multicenter randomized controlled trial conducted between 2014 and 2017, including 665 men with a prior negative SB and a persistent suspicion of PCa (suspicious digital rectal examination and/or prostate-specific antigen >4.0ng/ml). INTERVENTION: All patients underwent 3T mpMRI according to Prostate Imaging Reporting and Data System (PI-RADS) v2. Patients with PI-RADS ≥3 were randomized 1:1:1 for three TB techniques: MRI-TRUS fusion TB (FUS-TB), cognitive registration fusion TB (COG-TB), or in-bore MRI TB. FUS-TB and COG-TB were combined with repeated SBs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinically significant prostate cancer (csPCa) was defined as Gleason ≥3+4. Differences in detection rates of csPCa, clinically insignificant PCa (cisPCa), and overall PCa between TBs (FUS-TB and COG-TB) and repeated SBs were compared using McNemar's test. RESULTS AND LIMITATIONS: In the 152 patients who underwent both TB and SB, PCa was detected by TB in 47% and by SB in 32% (p<0.001, 95% confidence interval [CI]: 6.0-22%). TB detected significantly more csPCa than SB (32% vs 16%; p<0.001, 95% CI: 11-25%). Clinically significant PCa was missed by TB in 1.3% (2/152). Combining SB and TB resulted in detection rate differences of 6.0% for PCa, 5.0% for cisPCa, and 1.0% for csPCa compared with TB alone. CONCLUSIONS: In case of a persistent suspicion of PCa following a negative SB, TB detected significantly more csPCa cases than SB. The additional value of SB was limited, and only 1.3% of csPCa would have been missed when SB had been omitted. PATIENT SUMMARY: We evaluated the role of systematic biopsies and magnetic resonance imaging (MRI)-targeted biopsies for the diagnosis of prostate cancer in patients with prior negative systematic biopsies. MRI-targeted biopsies perform better in detecting prostate cancer in these patients. The value of repeated systematic biopsies is limited.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Exterkate L, Wegelin O, Barentsz JO, et al. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate? Eur Urol Oncol. 2019. PMID: 31239236. doi:10.1016/j.euo.2019.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。